Nasheed Mohammad Hossain MD

Hematologic Oncology

Physician

3400 Spruce StPhiladelphia, PA 19104
Phone+1 215-615-0063
Fax+1 215-349-8144

Dr. Hossain is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hossain's full profile Already have an account?

Summary

Dr. Nasheed Hossain is a hematologist based in Philadelphia, PA, specializing in hematologic oncology with a focus on allogeneic stem cell transplant and cellular immunotherapies. He completed his internal medicine residency at the University of Chicago and a fellowship in hematology and medical oncology at Temple University Hospital-Fox Chase Cancer Center and a transplant fellowship/immunology post-doc at Stanford University . Dr. Hossain has held academic roles as an Assistant Professor at the University of Pennsylvania and Loyola University Chicago. His research is published in various high-impact peer-reviewed journals, with topics including tumor lysis syndrome, hematopoietic cell transplantation, and CAR-T therapy, among others.

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
University of ChicagoResidency, Internal Medicine, 2010 - 2013
Case Western Reserve University School of MedicineClass of 2010

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 2013 - 2026
CA State Medical License 2016 - 2025
IL State Medical License 2018 - 2023
American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

Day-30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation.
Trent Wang, Anna C Ferreira, Nasheed M Hossain, Denggang Fu, Elizabeth G Hill
British Journal of Haematology. 2026-08-01
Naïve CD4T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.
Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho
Nature Communications. 2026-05-15
Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.
Jonathan A Baron, Leah Cohen, Monica Chelius, Ian Messing, John Mallon
Clinical Lymphoma, Myeloma & Leukemia. 2026-05-01

Abstracts/Posters

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
Nasheed Hossain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Nasheed Hossain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

‘Exciting’ Research Spotlights CAR-t’s Evolving Role in Blood Cancer TreatmentFebruary 22nd, 2023
Graft Versus Host Disease ResearchJune 17th, 2023
Research into Graft Versus Host Disease (GVHD)June 28th, 2023